Effect of walnut consumption on inflammation and oxidative stress in middle-aged and elderly people
Not Applicable
Completed
- Conditions
- Prevention of metabolic syndrome and anti-aging potential of walnut in middle-aged and elderly people.Not Applicable
- Registration Number
- ISRCTN17119161
- Lead Sponsor
- University of Medicine and Pharmacy Iuliu Ha?ieganu Cluj-Napoca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
- Caucasian adults, women and men aged 40-65 years2. With no known allergy to walnuts3. Provide informed consent4. Clinical characteristics: healthy individuals at MetS risk with at least one of the specific parameters present, including: 4.1. Abdominal obesity: waist circumference (WC) = 102 cm and = 88 cm for European men and women, respectively4.2. Hypertension: systolic blood pressure (SBP) = 130 mmHg or/and diastolic blood pressure (DBP) = 85 mmHg4.3. Dyslipidemia: TG = 150 mg/dL and high-density lipoprotein cholesterol (HDL-c) < 40 mg/dL in men or < 50 mg/dL in women4.4. Dysglycemia: fasting blood glucose (FBG) = 100 mg/dL
Exclusion Criteria
- Individuals with allergies to walnuts, other tree nuts, and peanuts or following restric-tive diets for food allergies, food intolerances (lactose, fructose, gluten)2. Diets for chronic gastrointestinal or kidney disease, vegetarians, or other types of diet that could interfere with study results, as well as those with current or recent eating disorders (last 6 months prior to the start of the study). 3. Individuals with current chronic diseases: chronic intestinal diseases (ulcerative colitis, Crohn's disease), chronic renal disease, CVD, pulmonary disease, Type 1 or 2 diabetes, cancer, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), gallbladder disorders (gallbladder lithiasis, biliary dyskinesia, and acute or chronic cholecystitis)4. Drug treatments (insulin therapy, hypoglycemic and/or hypolipidemic treatments, chronic treatment with non-steroidal and/or steroidal an-ti-inflammatory drugs)5. Concomitant use or at least two weeks prior to the start of the study of dietary supplements (vitamins or minerals, anti-inflammatory and/or antiox-idant compounds, including fish oil, omega-3 fatty acids, resveratrol, curcumin, vita-min C, selenium, zinc, as well as dietary fiber, probiotics, symbiotics).6. Pregnancy7. Smoking 8. Chronic alcohol consumption
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Assessment of blood vascular cell adhesion molecule (s-VCAM) levels using Elisa Kit at baseline and at the end of each intervention period.
- Secondary Outcome Measures
Name Time Method